Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
Discoveries of isocitrate dehydrogenase (IDH) mutation, co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p19q), O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, and histone H3-K27M mutation have led to a better understanding of the molecular aberrations associated with Brain Tumors.
Pondering over changing dynamics of the Brain Tumor market? Request a Sample for more @
A Brain Tumor, also known as an intracranial tumor, or central nervous system (CNS) tumor, is a group of diseases that share the common link of abnormal development of mass lesions in the brain, spinal cord, or its coverings. Symptoms of a Brain Tumor can be general or specific and vary depending upon the location of the Brain Tumor. A general symptom includes headaches, seizures, personality or memory changes, nausea or vomiting, fatigue, drowsines
Novartis Pharma AG: Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
1 non-small cell lung cancer
2,3
help
1 beta (IL-1ß) in pro-tumor inflammation i
n lung cancer, with multiple clinical trials investigating
canakinumab in
2
-5
Basel, March 9, 2021 - Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS)
1. The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy
19. More people die of lung cancer every year than any other cancer type
11. Novartis is committed to developing best-in-class treatments for lung cancer patients around the world. With a focus on both targeted, personalized medicine and the role of newer, immuno-oncology therapies, the lung cancer drug development program at Novartis is among the most robust in the industry. With research activities informed by long-term relationships with leading lung cancer thought leaders and patient advocates, Novartis is focused on reimagining the treatment of lung cancer.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “potentially,” “can,” “will,” “expected,” “committed,” “evaluating,” “continue,” “ongoing,” “approximately,” or similar terms, or by expre
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MDxHealth Reports Financial Year 2020 Results and Provides Outlook for 2021
MDxHealth (R)March 3, 2021 GMT
NEWS RELEASE - REGULATED INFORMATION 3 MARCH 2021, 07:00 A.M. CET
Conference call with Q&A today at 08:00 CET / 07:00 GMT, details provided below
IRVINE, CA, and HERSTAL, BELGIUM – March 3, 2021 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced its financial results for the year ended December 31, 2020 and provided a business update and outlook for 2021.
Michael K. McGarrity, CEO of MDxHealth, commented: “While 2020 has indeed presented challenges due to the COVID-19 pandemic and the impact on the market, we have made significant progress based on our commitment to execute on our stated goals of advancing our turnaround of every operating discipline within the business.
New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.